Mode
Text Size
Log in / Sign up

Clinical Trial Search

Completed trials with posted results — search by concept, filter by the parameters that matter at the bedside.

Phase
Intervention
Population
Results posted

30 closest matches · ranked by relevance

Phase 2 N=73 Fibrin Sealant Vascular Surgery Study

Adjunct to Hemostasis in Vascular Surgery (Synthetic Vascular Grafts)
Primary: Percentage of Participants Achieving Hemostasis at 4 Minutes After Treatment Application at the Study Suture Line. — 46.2; 62.5; 34.8; 30.8 percentage of participants
Baxter Healthcare Corporation Results Nov 2012 16.3% serious AE View details

Phase 4 N=252 The Bioseal Vascular Study

Cardiovascular Bleeding · Vascular Bleeding · Hemorrhage
Primary: Hemostasis at the Target Bleeding Site (TBS) at 10 Minutes Following the Completion of Treatment Application. — 96; 88.2 percentage of patients
Ethicon, Inc. Results Sep 2016 9.5% serious AE View details

N/A N=158 Progel Vascular Sealant

Aortic Valve Stenosis · Aneurysm of Ascending Aorta · Aortic Valve Disorder
Primary: Time to Achieve Hemostasis at the Aortic Anastomotic Suture Line From the Time Surgical Clamps Are Released to Cessation of Leakage at the Treated Anastomotic Site With…
C. R. Bard Results Jan 2017 51.3% serious AE View details

Phase 3 N=140 FS VH S/D 500 S-apr in Vascular Surgery

Hemostasis in Participants Receiving Peripheral Vascular Expanded Polytetrafluoroethylene (ePTFE) Graft Prostheses
Primary: Percentage of Participants Who Achieved Hemostasis at 4 Minutes Post Treatment Application. — 62.9; 31.4 Percentage of participants — p=<0.0001
Baxter Healthcare Corporation Results Nov 2012 27.1% serious AE View details

Phase 2 N=70 Fibrin Sealant VH S/D 500 S-apr in Hepatic Resection

Bleeding (Oozing) in Hepatic Resection
Primary: Percentage of Participants With Intraoperative Hemostasis at 4 Minutes After Treatment Application — 82.9; 37.1 percentage of participants — p=<0.001
Baxter Healthcare Corporation Results Feb 2013 28.6% serious AE View details

Phase 3 N=156 The Fibrin Pad CV Phase III Study

Cardiovascular Disease
Primary: Number of Participants With Hemostasis at the Target Bleeding Site (TBS) at 3 Minutes Following Treatment Application. — 57; 36 Participants — p=0.0001
Ethicon, Inc. Results Aug 2017 41.7% serious AE View details

Phase 2 N=42 The Fibrin Pad Cardiovascular Study

Cardiovascular Disease
Primary: Hemostasis at the Target Bleeding Site (TBS) at 3 Minutes Following Treatment Application. — 12; 6; 5 Participants
Ethicon, Inc. Results Mar 2018 45.2% serious AE View details